Li LC, Li J, Gao J (2014) Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 351(2):336–343. https://doi.org/10.1124/jpet.114.218370

Article  CAS  PubMed  Google Scholar 

Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103(13):5060–5065. https://doi.org/10.1073/pnas.0511167103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johannes L, Jacob R, Leffler H (2018) Galectins at a glance. J Cell Sci 131(9):jcs208884. https://doi.org/10.1242/jcs.208884

Article  CAS  PubMed  Google Scholar 

Mori Y, Akita K, Yashiro M, Sawada T, Hirakawa K, Murata T, Nakada H (2015) Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 protein enhances phosphorylation of extracellular signal-regulated Kinase 1/2 (ERK1/2) and Akt, promoting tumor cell malignancy. J Biol Chem 290(43):26125–26140. https://doi.org/10.1074/jbc.M115.651489

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slack RJ, Mills R, Mackinnon AC (2021) The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol 130:105881. https://doi.org/10.1016/j.biocel.2020.105881

Article  CAS  PubMed  Google Scholar 

Peng W, Wang HY, Miyahara Y, Peng G, Wang RF (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68(17):7228–7236. https://doi.org/10.1158/0008-5472.Can-08-1245

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC (2019) An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res 79(7):1480–1492. https://doi.org/10.1158/0008-5472.Can-18-2244

Article  CAS  PubMed  Google Scholar 

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P (2017) Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun 8(1):793. https://doi.org/10.1038/s41467-017-00925-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N (2019) Soluble ST2 and galectin-3 and progression of CKD. Kidney Int Rep 4(1):103–111. https://doi.org/10.1016/j.ekir.2018.09.013

Article  PubMed  Google Scholar 

Andre C, Piver E, Perault R, Bisson A, Pucheux J, Vermes E, Pierre B, Fauchier L, Babuty D, Clementy N (2018) Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. J Transl Med 16(1):299. https://doi.org/10.1186/s12967-018-1675-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boza-Serrano A, Ruiz R, Sanchez-Varo R, García-Revilla J, Yang Y, Jimenez-Ferrer I, Paulus A, Wennström M, Vilalta A, Allendorf D, Davila JC, Stegmayr J, Jiménez S, Roca-Ceballos MA, Navarro-Garrido V, Swanberg M, Hsieh CL, Real LM, Englund E, Linse S, Leffler H, Nilsson UJ, Brown GC, Gutierrez A, Vitorica J, Venero JL, Deierborg T (2019) Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol 138(2):251–273. https://doi.org/10.1007/s00401-019-02013-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A (2015) Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med 240(8):1019–1028. https://doi.org/10.1177/1535370215593826

Article  CAS  Google Scholar 

Noguchi K, Tomita H, Kanayama T, Niwa A, Hatano Y, Hoshi M, Sugie S, Okada H, Niwa M, Hara A (2019) Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation. PLoS One 14(1):e0210971. https://doi.org/10.1371/journal.pone.0210971

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M, Rossi GP (2015) Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 35(3):725–732. https://doi.org/10.1161/atvbaha.114.304964

Article  CAS  PubMed  Google Scholar 

Medvedeva EA, Berezin II, Surkova EA, Yaranov DM, Shchukin YV (2016) Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol 64(6):595–602

PubMed  Google Scholar 

Al-Sharaky DR, Younes SF (2016) Sensitivity and specificity of galectin-3 and glypican-3 in follicular-patterned and other thyroid neoplasms. J Clin Diagn Res 10(3):EC06–10. https://doi.org/10.7860/jcdr/2016/18375.7430

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaneko N, Gotoh A, Okamura N, Matsuo E, Terao S, Watanabe M, Yamada Y, Hamami G, Nakamura T, Ikekita M, Okumura K, Nishimura O (2013) Potential tumor markers of renal cell carcinoma: alpha-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 20(5):530–535. https://doi.org/10.1111/j.1442-2042.2012.03206.x

Article  CAS  PubMed  Google Scholar 

Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6(4):1389–1393

CAS  PubMed  Google Scholar 

Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C, Kiss R (2008) The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 44(1):86–93. https://doi.org/10.1016/j.oraloncology.2006.12.014

Article  CAS  PubMed  Google Scholar 

MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180(4):2650. https://doi.org/10.4049/jimmunol.180.4.2650

Article  CAS  PubMed  Google Scholar 

Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172(2):288–298. https://doi.org/10.2353/ajpath.2008.070726

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185(5):537–546. https://doi.org/10.1164/rccm.201106-0965OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA, Kahl-Knutsson B, van Hattum H, van Scherpenzeel M, Pieters RJ, Sethi T, Schambye H, Oredsson S, Leffler H, Blanchard H, Nilsson UJ (2016) Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. ChemBioChem 17(18):1759–1770. https://doi.org/10.1002/cbic.201600285

Article  CAS  PubMed  Google Scholar 

Hirani N, Nicol L, MacKinnon AC, Ford P, Schambye H, Pedersen Nilsson U, Leffler H, Thomas T, Knott O, Gibbons M, Simpson J, Maher T (2016) TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in (IPF) patients study. QJM 109(suppl_1):S16. https://doi.org/10.1093/qjmed/hcw127.003

Article  Google Scholar 

Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gavelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM (2020) Target-inhibition of Galectin-3 by Inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J 57(5):2002559. https://doi.org/10.1183/13993003.02559-2020

Article  CAS  Google Scholar 

Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O’Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T, Dhaliwal K (2023) An inhaled galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib/IIa randomized controlled clinical trial (DEFINE). Am J Respir Crit Care Med 207(2):138–149. https://doi.org/10.1164/rccm.202203-0477OC

Article  CAS  PubMed  Google Scholar 

Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S (2022) Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease. J Med Chem 65(19):12626–12638. https://doi.org/10.1021/acs.jmedchem.2c00660

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mabbitt J, Roper JA, Slack RJ (2022) Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1. J Clin Oncol 40(16_suppl):2607. https://doi.org/10.1200/JCO.2022.40.16_suppl.2607

Article  Google Scholar 

Stasenko M, Smith E, Yeku O, Park KJ, Laster I, Lee K, Walderich S, Spriggs E, Rueda B, Weigelt B, Zamarin D, Rao TD, Spriggs DR (2021) Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep 11(1):3718. https://doi.org/10.1038/s41598-021-82686-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, Díez J, Wang TJ, Ho JE (2021) Galectin-3 inhibition with modified citrus pectin in hypertension. JACC Basic Transl Sci 6(1):12–21. https://doi.org/10.1016/j.jacbts.2020.10.006

Article  PubMed  PubMed Central  Google Scholar